ClinConnect ClinConnect Logo
Search / Trial NCT06161116

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Launched by MERCK SHARP & DOHME LLC · Nov 29, 2023

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called MK-6194 for adults with Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues. The main goal is to see if MK-6194 works better than a placebo (a fake treatment) in helping people with SLE feel better by the end of 28 weeks. To be eligible for the trial, participants must have been diagnosed with SLE for at least six months, be currently taking certain medications for their condition, and have specific symptoms related to SLE, such as a rash or swollen joints.

Participants in the trial will receive either MK-6194 or a placebo and will be monitored closely by healthcare professionals. It's important to note that some individuals may not qualify, especially those with serious heart or lung conditions, certain infections, or who are taking multiple immune-suppressing medications. This trial is currently recruiting participants, and those who are eligible can expect regular check-ins and assessments to track their progress and any side effects from the treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Has a diagnosis of systemic lupus erythematosus (SLE) ≥6 months prior to Screening.
  • Is taking at least 1 background therapy (1 immunosuppressant or dapsone and/or 1 antimalarial and/or oral corticosteroids) for SLE.
  • Has + antinuclear antibody (+ANA) (titer ≥1:80) or positive anti-double-strand deoxyribonucleic acid (dsDNA) antibody or positive anti-Sm antibody, or positive anti-SSA/Ro antibody.
  • Has the presence of at least one of the following manifestations of SLE: Active lupus rash with CLASI-A erythema and scale/hypertrophy combined score \>2, or \>2 tender and swollen joints in wrists, metacarpophalangeals (MCPs), or proximal interphalangeals (PIPs).
  • Has a hybrid Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) total score of ≥6 and clinical hybrid SLEDAI score of ≥4.
  • Exclusion Criteria:
  • Has a concurrent clinically significant disease or clinically relevant laboratory abnormalities, or a history of any illness or medical condition that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • Has symptomatic heart failure (New York Heart Association class III or IV) or myocardial infarction or unstable angina pectoris within 6 months prior to Screening.
  • Has a severe chronic pulmonary disease requiring oxygen therapy.
  • Has a transplanted organ which requires continued immunosuppression.
  • Has a known systemic hypersensitivity to IL-2, or modified IL-2 including MK-6194, or its inactive ingredients.
  • Has a known history of lymphoproliferative disease, including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly.
  • Has drug-induced cutaneous lupus erythematosus (CLE) and/or drug-induced SLE in the setting of continued treatment with a causative agent.
  • Has active or unstable neuropsychiatric lupus including but not limited to the following: seizure, new or worsening impaired level of consciousness, psychosis, delirium or confused state, aseptic meningitis, cranial neuropathy, cerebrovascular accident, ascending or transverse myelitis, chorea, cerebellar ataxia, mononeuritis multiplex, or demyelinating syndromes.
  • Has a diagnosis of Antiphospholipid Syndrome with history of vascular thrombosis, catastrophic APS, or pregnancy morbidity within 6 months prior to Screening.
  • Has a history of any malignancy, except for successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix.
  • Has an active or clinically significant infection requiring hospitalization or treatment with anti-infectives.
  • Has evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
  • Has confirmed or suspected COVID-19 infection.
  • Has had major surgery within 3 months prior to Screening or has a major surgery planned during the study.
  • Is taking more than 1 immunosuppressant.
  • Is taking more than 1 oral NSAID (excluding low-dose aspirin \[\<350 mg/day\]) or is taking daily oral nonsteroidal anti-inflammatory drug (NSAID) at greater than the maximum recommended dosage.
  • Is currently on any chronic systemic (oral or IV) anti-infective therapy for chronic active infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical mycobacteria).

About Merck Sharp & Dohme Llc

Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines and vaccines that address unmet medical needs. With a strong focus on research and development, Merck Sharp & Dohme leverages advanced science and technology to enhance patient outcomes across various therapeutic areas, including oncology, infectious diseases, and cardiovascular health. Committed to ethical practices and regulatory compliance, the company actively engages in clinical trials to advance medical knowledge and improve health care for patients worldwide.

Locations

Merida, Yucatan, Mexico

Barranquilla, Atlantico, Colombia

La Palma, California, United States

Clearwater, Florida, United States

Charlotte, North Carolina, United States

Charlotte, North Carolina, United States

Sherbrooke, Quebec, Canada

Chiba, , Japan

Desoto, Texas, United States

La Serena, Coquimbo, Chile

Santiago, Region M. De Santiago, Chile

La Serena, Coquimbo, Chile

Izumo, Shimane, Japan

Okayama, , Japan

Santiago, Region M. De Santiago, Chile

Saint Priest En Jarez, Loire, France

Bydgoszcz, Kujawsko Pomorskie, Poland

Lublin, Lubelskie, Poland

A Coruña, La Coruna, Spain

Valencia, Valenciana, Comunitat, Spain

Denver, Colorado, United States

Plantation, Florida, United States

Temuco, Araucania, Chile

Nagoya, Aichi, Japan

Shimotsuga, Tochigi, Japan

Krakow, Malopolskie, Poland

Bialystok, Podlaskie, Poland

Barcelona, , Spain

Sevilla, , Spain

Sendai Shi, Miyagi, Japan

Chiba, , Japan

Lyon, Rhone Alpes, France

Guatemala, , Guatemala

Guatemala, , Guatemala

Rome, Roma, Italy

Osaka, , Japan

Valladolid, , Spain

Ciudad De Guatemala, , Guatemala

Lille, Nord, France

Santiago, Region M. De Santiago, Chile

Taiping, Perak, Malaysia

Poznan, Wielkopolskie, Poland

Pessac, Aquitaine, France

Montpellier, Herault, France

Siena, Toscana, Italy

Kuantan, Pahang, Malaysia

Bytom, Slaskie, Poland

Poznan, Wielkopolskie, Poland

Guiyang, Guizhou, China

Barranquilla, Atlantico, Colombia

Chía, Cundinamarca, Colombia

Toulouse, Haute Garonne, France

Kawasaki, Kanagawa, Japan

Zipaquira, Cundinamarca, Colombia

Cali, Valle Del Cauca, Colombia

Itabashiku, Tokyo, Japan

Osaka, , Japan

San M. De Tucuman, Tucuman, Argentina

Porto Alegre, Rio Grande Do Sul, Brazil

Temuco, Araucania, Chile

Beijing, Beijing, China

Guangzhou, Guangdong, China

Nantong, Jiangsu, China

Shanghai, Shanghai, China

Medellín, Antioquia, Colombia

Cali, Valle Del Cauca, Colombia

Tomigusuku, Okinawa, Japan

Shinagawa, Tokyo, Japan

Lembah Pantai, Kuala Lumpur, Malaysia

San Luis Potosí, San Luis Potosi, Mexico

Distrito Federal, , Mexico

Rosario, Santa Fe, Argentina

Mendoza, , Argentina

São José Do Rio Preto, Sao Paulo, Brazil

Recoleta, Region M. De Santiago, Chile

Hengyang, Hunan, China

Baotou, Inner Mongolia, China

Pingxiang, Jiangxi, China

Roma, Lazio, Italy

Mar Del Plata, Buenos Aires, Argentina

Tampa, Florida, United States

Porto Alegre, Rio Grande Do Sul, Brazil

Sao Bernardo Do Campo, Sao Paulo, Brazil

Lanzhou, Gansu, China

Shijiazhuang, Hebei, China

Wuhan, Hubei, China

Chengdu, Sichuan, China

Tianjin, Tianjin, China

Memphis, Tennessee, United States

Guangzhou, Guangdong, China

Xi'an, Shaanxi, China

Guadalajara, Jalisco, Mexico

Guadalajara, Jalisco, Mexico

Wuhan, Hubei, China

Napoli, , Italy

Santa Fe, , Argentina

Bengbu, Anhui, China

Chang Chun, Jilin, China

Taiyuan, Shanxi, China

Tujunga, California, United States

La Serena., Coquimbo, Chile

Houston, Texas, United States

Bengbu, Anhui, China

Luoyang, Henan, China

Lake Charles, Louisiana, United States

Grand Blanc, Michigan, United States

Mesquite, Texas, United States

Guadalajara, Jalisco, Mexico

Chihuahua, , Mexico

Baytown, Texas, United States

Rozzano, Milano, Italy

León, Guanajuato, Mexico

Iloilo, , Philippines

Covina, California, United States

Mexico City, Distrito Federal, Mexico

Lipa, Batangas, Philippines

Quezon City, National Capital Region, Philippines

Lipa City, Batangas, Philippines

Hefei, Anhui, China

Roma, , Italy

Oklahoma City, Oklahoma, United States

Osaka, , Japan

Kadikoy, Istanbul, Turkey

Ankara, , Turkey

Sakarya, , Turkey

Santa Fe., Santa Fe, Argentina

Sherbrooke, Quebec, Canada

Santiago., Region M. De Santiago, Chile

Rosario, Santa Fe, Argentina

Guadalajara, Jalisco, Mexico

Warszawa, Mazowieckie, Poland

Ankara, , Turkey

Shinagawa, Tokyo, Japan

Chiba, , Japan

Monterrey, Nuevo Leon, Mexico

Atlanta, Georgia, United States

La Jolla, California, United States

La Serena., Coquimbo, Chile

Firenze, , Italy

Mexico City, Distrito Federal, Mexico

La Jolla, California, United States

Santiago., Region M. De Santiago, Chile

Guangzhou, Guangdong, China

Baotou, Inner Mongolia, China

Napoli, , Italy

Merida, Yucatan, Mexico

Cheras, Kuala Lumpur, Malaysia

Padova, Veneto, Italy

Cuiaba, Mato Grosso, Brazil

Valencia, , Spain

Patients applied

0 patients applied

Trial Officials

Medical Director

Study Director

Merck Sharp & Dohme LLC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported